Hypertension. Essential (primary) hypertension
Conditions
Interventions
Intervention 1: Intervention group: Receiving routine drug treatment + enriched antioxidant extract of Ziziphus jujuba fruit for 12 weeks (3 months). Patients will be evaluated for symptoms at 14 week
Sponsors
Golestan University of Medical Sciences
South Khorasan Academic center for education, culture and research
Food and Bio-Nanotech International Research Center (Fabiano)
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 120 mmHg < blood pressure < mmHg 160 (Pre- and stage 1 hypertension) Age over 18, female or male Voluntary participation and written consent
Exclusion criteria
Exclusion criteria: Other heart diseases Secondary blood pressure Serum Potassium > 5.5 mmol/L or < 3.5 mmol/L double serum creatinine in the last 6 months Severe complications of diabetes or serious macrovascular events within 6 months (for example, cerebral hemorrhage, cerebral infarction, or acute myocardial infarction) Recent infection in the last 4 weeks Primary or secondary kidney disease (e.g., IgA nephropathy, membranous nephropathy, or lupus nephritis) Any cancer and malignancy Severe mental disorder Pregnant or lactating women or women who are planning to become pregnant or women who are not using appropriate contraceptive methods Drug allergies or jujube allergies Participate in other clinical trials Use of other herbal medicines to control the symptoms of the present disease History of smoking, drugs Other conditions that the researchers considered inappropriate in this clinical study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood pressure. Timepoint: 0: Start studying and receiving medication (in person),1: 2 weeks after receiving stage 1 medication (in person), 3: Week 8 End of stage 2 drug treatment course (in person), 4: Week 12 after receiving the drug stage 3 (face-to-face visit), 5: First follow-up - 2 weeks after receiving the drug (week 14) (telephone follow-up), 6: Second follow-up - 4 weeks after receiving the drug (week 16) (face-to-face visit). Method of measurement: Mercury sphygmomanometer. | — |
Secondary
| Measure | Time frame |
|---|---|
| SCr. Timepoint: 0: Start studying and receiving medication (in person),1: 2 weeks after receiving stage 1 medication (in person), 3: Week 8 End of stage 2 drug treatment course (in person), 4: Week 12 after receiving the drug stage 3 (face-to-face visit), 5: First follow-up - 2 weeks after receiving the drug (week 14) (telephone follow-up), 6: Second follow-up - 4 weeks after receiving the drug (week 16) (face-to-face visit). Method of measurement: Blood and urine tests.;EGFR. Timepoint: 0: Start studying and receiving medication (in person),1: 2 weeks after receiving stage 1 medication (in person), 3: Week 8 End of stage 2 drug treatment course (in person), 4: Week 12 after receiving the drug stage 3 (face-to-face visit), 5: First follow-up - 2 weeks after receiving the drug (week 14) (telephone follow-up), 6: Second follow-up - 4 weeks after receiving the drug (week 16) (face-to-face visit). Method of measurement: Blood and urine tests.;Serum Albumin. Timepoint: 0: Start studying and receiving medication (in person),1: 2 weeks after receiving stage 1 medication (in person), 3: Week 8 End of stage 2 drug treatment course (in person), 4: Week 12 after receiving the drug stage 3 (face-to-face visit), 5: First follow-up - 2 weeks after receiving the drug (week 14) (telephone follow-up), 6: Second follow-up - 4 weeks after receiving the drug (week 16) (face-to-face visit). Method of measurement: Blood and urine tests.;Serum Potassium. Timepoint: 0: Start studying and receiving medication (in person),1: 2 weeks after receiving stage 1 medication (in person), 3: Week 8 End of stage 2 drug treatment course (in person), 4: Week 12 after receiving the drug stage 3 (face-to-face visit), 5: First follow-up - 2 weeks after receiving the drug (week 14) (telephone follow-up), 6: Second follow-up - 4 weeks after receiving the drug (week 16) (face-to-face visit). Method of measurement: Blood and urine tests.;EGC. Timepoint: 0: Start studying and receiving medication (in person),1: | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Ayesheh Enayati
Gorgan University of Medical Sciences
Outcome results
None listed